gAcrp30, Recombinant, Human (Globular Adipocyte Complement-related Protein of 30kD, apm-1, Adipolean)

gAcrp30 is a naturally occurring globular protein, obtained by proteolytic processing of adiponectin. Adiponectin is produced and secreted exclusively by adipocytes, and is a relatively abundant plasma protein, accounting for up to 0.05% of total serum protein. Like Adiponectin, gAcrp30 is capable of decreasing hyperglycemia and reversing insulin resistance. Additionally, gAcrp30 has been shown to be an important factor in promoting fat loss by signaling muscle to absorb and burn Free-Fatty Acids (FFAs). The signaling receptors for adiponectin and gAcrp30 have recently been identified and names AdipoR1 and AdipoR2. AdipoR2 is predominantly expressed in the liver. Recombinant human gAcrp30/Adipolean is a 16.6kD protein consisting of 145 amino acid residues.\n\nBiological Activity:Determined by its ability to inhibit the proliferation of murine myeloid cell lines M1. The ED50 for this effect is 1.0-3.0ug/ml.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (1EU/ug)\n\nForm: \nSupplied as a lyophilized powder.\n\nAA Sequence: \nMKGEPGEGAY VYRSAFSVGL ETYVTIPNMP IRFTKIFYNQ QNHYDGSTGK FHCNIPGLYY FAYHITVYMK DVKVSLFKKD KAMLFTYDQY QENNVDQASG SVLLHLEVGD QVWLQVYGEG ERNGLYADND NDSTFTGFLL YHDTN\n \nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Reconstitute to nominal volume by adding sterile buffer. Aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. \n\nCountry of Origin: USA

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

G1016-02B

Size

5ug

Form

Supplied as a lyophilized powder. Reconstitute with sterile dH2O.

Purity

(same/more than) 98% by SDS-PAGE and HPLC. Endotoxin: \n(same/less than) 0.1ng/ug (1EU/ug).

References

1. Rakatzi, I.,et al., Diabetologia 47(2): 249-58 (2004). 2. Hu, X.B.,et al., ACTA BIOCHIMICA BIOPHYSICA SINICA 35(11): 1023-1028 (2003). 3. Tomas, E., et al., PNAS USA 99(25): 16309-13 (2002). 4. Tsao, T.S., et al., J. Biol. Chem. 277(33): 29359-62 (2002). 5, Fruebis, J., et al., PNAS USA 98(4): 2005-10 (2001).